XML 73 R45.htm IDEA: XBRL DOCUMENT v3.25.4
Revenue Recognition - Schedule of net revenue from collaboration arrangement (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Revenue Recognition and Collaborative Arrangements      
Total royalty revenue $ 411,328 $ 358,711 $ 310,463
Royalty Revenue      
Revenue Recognition and Collaborative Arrangements      
Less: amortization of capitalized fees paid (13,800) (13,800) (13,800)
Total royalty revenue 236,479 241,733 238,846
GSK | Royalty Revenue      
Revenue Recognition and Collaborative Arrangements      
Total royalties 250,302 255,556 252,669
Less: amortization of capitalized fees paid (13,823) (13,823) (13,823)
Total royalty revenue 236,479 241,733 238,846
GSK | RELVAR/BREO      
Revenue Recognition and Collaborative Arrangements      
Total royalties 204,021 207,925 208,042
GSK | ANORO      
Revenue Recognition and Collaborative Arrangements      
Total royalties $ 46,281 $ 47,631 $ 44,627